Do analysts rate the NAB share price a buy after its FY21 result?

Are NAB shares a good buy after the company's FY21 report?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

National Australia Bank Ltd (ASX: NAB) reported its FY21 result to investors this week. Analysts have had a look – do they rate the NAB share price as a buy?

Firstly, let's see how the result stacked up.

Young girl peeps over the top of her red piggy bank, ready to put coins in it.

Image source: Getty Images

NAB FY21 result

The big four ASX bank said that it generated $6.36 billion of statutory net profit.

Meanwhile, the cash earnings came to $6.56 billion – that was an increase of 76.8% year on year. Excluding FY20's large notable items, NAB's cash earnings increased by 38.6%.

NAB explained that its total revenue declined by 2.2%. Higher volumes were more than offset by lower markets and treasury income which was challenged by more limited trading opportunities.

The net interest margin (NIM) declined by 6 basis points to 1.71%. However, excluding the 6% reduction from markets and treasury (which includes the impact of holding higher liquid assets), NIM was flat which reflected lower funding and deposit costs and home repricing. But this was partially offset by the impact of the low interest rate environment combined with "home lending competitive pressures" and a shift towards more fixed-rate lending.

Expenses officially fell 13.2%. Excluding large notable items in FY20, expenses actually rose 1.8% with important drivers such as performance-based compensation provisions, as well as hiring more people to support growth, partly offset by productivity benefits and lower restructuring-related costs.

During the worst of the COVID-19 crash last year, the NAB share price fell heavily and there was a worry of bad debts. In this result, NAB's credit impairment charge was a write-back ­of $217 million compared to an FY20 charge of $2.76 billion.

NAB said its ratio of 90+ days past due and gross impaired assets to gross loans and acceptances reduced by 9 basis points to 0.94%.

The big four bank said:

The economic outlook is improving with restrictions easing. But uncertainties exist including the impact of tapering support and the extent and breadth of the rebound. To reflect this, collective provisions remain prudent at 1.35% of credit risk weighted assets.

Balance sheet and dividend

NAB's balance sheet continues to strengthen. Its overall common equity tier 1 (CET1) ratio was 13% at the end of FY21, up 153 basis points over the year. That includes 29 basis points from the net proceeds of the sale of MLC Wealth, less the acquisition of 86 400.

However, it's expected that the net pro forma CET1 ratio will be reduced by around 75 basis points by the acquisition of Citigroup's Australian consumer basis as well as the remaining $2 billion share buyback, less proceeds from its BNZ Life sale.

NAB decided to more than double its annual dividend, from $0.60 per share in FY20 to $1.27 per share in FY21. This represented a cash dividend payout ratio of 63.7% of continuing operations.

Is the NAB share price a buy?

Opinions are somewhat mixed on the bank after the result.

For example, Citi is 'neutral' on NAB shares, with a price target of $29.50. It thinks it is one of the better big four banks after this result, but there remains a lot of competition in the property loan space. Citi is expecting slight underlying growth in FY22. The broker thinks NAB will pay an FY22 annual dividend per share of $1.45.

However, analysts at Macquarie Group Ltd (ASX: MQG) think the NAB share price is a buy, with a price target of $30.50. Macquarie also believes NAB is doing better than its big competitors. But, despite the buy rating, Macquarie actually thinks NAB will generate less profit and pay a small dividend in FY22 compared to Citi's estimates. Macquarie has projected an annual dividend per share of $1.35 from NAB in the current financial year.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

A little girl has a huge smile and a giant lollipop.
Broker Notes

6 ASX shares tipped by brokers to rise 34% to 87%

Post-earnings season, brokers have updated their 12-month price targets on scores of stocks.

Read more »

Happy businessman fist pumping while looking at a tablet.
Broker Notes

2 ASX shares tipped to return 19% to 47%

Recent sell-offs have caught Morgans’ attention, with the broker now rating both shares as buys.

Read more »

Man sitting in a plane looking through a window and working on a laptop.
Broker Notes

Buy, hold, sell: Dicker Data, Polynovo, Flight Centre shares

Here's what the experts think.

Read more »

Two scientists analysing results on a computer screen.
Healthcare Shares

3 ASX healthcare shares to buy with 25% to 100% upside as sector rebound races higher

After slumping to a 9-year low on 3 June, healthcare shares have rallied by an extraordinary 42%.

Read more »

A baby's eyes open wide in surprise as it sucks on a milk bottle.
Broker Notes

How high could Bubs Australia shares go, according to Bell Potter?

A key approval is expected to boost the Bubs share price.

Read more »

a woman in a business suit looks wide eyed and interested as she holds a tin can with string to hear ear listening to some news.
Broker Notes

UBS names its 10 top ASX picks for the next 3-6 months

Here are the 10 ASX shares UBS thinks could outperform.

Read more »

Happy teen friends jumping in front of a wall.
Broker Notes

Guess which ASX stock could rise 85%

Bell Potter sees significant upside from this stock.

Read more »

Buy the dip written on a yellow sign.
Broker Notes

Down 43%! 4 reasons to buy the BIG dip in Pro Medicus shares today

A leading expert believes Pro Medicus shares are well-place to rebound.

Read more »